Navigation Links
Prozac Unplugged

Prozac, the popular drug for depression has been studied by researchers, in the manner with which it acts in the brain. Researchers from the Cold Spring Harbor Laboratory// in Long Island, New York, have found that the drug causes the production of immature brain cells.

This could pave the way for the birth of new treatment measures for depression, and Alzheimer's. The researchers, as part of their study, analyzed proteins that were produced by several cells in the brain of adult mice. Prozac, as discovered by the scientists, causes the production of certain cells called the ANP’s or amplifying neural progenitors.

The researchers are now testing other antidepressants and new drugs to establish whether they act in the same way. Lead researcher Dr Grigori Enikolopov said “Prozac is not a panacea, it does not work for everybody. By defining the drug's chief target we are giving a clearer idea of how perhaps to design new anti-depressant drugs and therapies."

Paul Farmer, chief executive of the mental health charity Mind, said: "All new research on drugs is interesting, but it's worth remembering that 'talking treatments', such as cognitive behavioral therapy, are the recommended first line treatment for many cases of depression. Unfortunately, waiting lists for these are often very long."
'"/>




Page: 1

Related medicine news :

1. Prozac miracle could end in disaster
2. Drug Prozac was found to control anger in post-stroke patients
3. Ultimate Destination of anti-depressant, Prozac
4. Prozac Gets Conditional Clearance For Treating Children
5. Prozac-popping Elders at Higher Risk of Fractures
6. Tsunami Unplugged: Natural Disasters Favor the Under-privileged
7. The Dengue Virus Unplugged
8. The Bovine DNA Sequence Unplugged
9. Liver Regeneration Unplugged
10. Gain from Pain - Migraine Unplugged
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether Education Partners’ ... the field must first improve teacher preparation program design. It then asserts that ... that decades of input- and outcome-based research has failed to improve teacher education. ...
(Date:3/28/2017)... ... March 28, 2017 , ... India’s ... technology to directly address the resolution to globally reduce the harmful use of ... compound of FDA and TTB approved ingredients that when infused into alcohol, renders ...
(Date:3/28/2017)... WASHINGTON, DC (PRWEB) , ... March 28, 2017 ... ... call on elected representatives in state legislatures and Congress to protect parental rights ... the public health and safety in America. , The demonstration coincides with a ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of all holidays (IBT World Travel Trends Report). As travelers visit both urban ... range in temperatures, and prolonged sun exposure. In response, the outdoor industry has ...
(Date:3/28/2017)... ... 2017 , ... Via Oncology, the leading provider of oncology ... public-facing tool for analyzing the costs of various drug regimens in cancer care. ... patients, providers, insurers and pharmaceutical companies about the estimated costs of treatment options. ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... DUBLIN , Mar 29, 2017 Research ... Global Market - Forecast to 2023" report to their offering. ... The ablation ... CAGR to reach $20,995.5 million by 2023. Ablation ... wide range of purposes, from cancerous or diseased tissue removal, to ...
(Date:3/29/2017)...  Spiral Therapeutics, Inc. today announced the signature ... for the worldwide exclusive rights to Bionure,s lead ... of otolaryngology for aggregate payments of up to ... provides Spiral with the option to license two ... Under the terms of the agreement, Spiral will ...
(Date:3/29/2017)... 2017   Royal Philips (NYSE: PHG, ... and PathAI, a company that develops artificial intelligence ... to develop solutions that improve the precision and ... diseases. The partnership aims to build deep learning ... artificial intelligence to be applied to massive pathology ...
Breaking Medicine Technology: